Erlotinib is a highly potent, orally active epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) approved worldwide for advanced NSCLC treatment following chemotherapy failure. This evidence concerns the gene EGFR and non-small cell lung carcinoma.